羟氯喹剂量与活动性狼疮住院风险
在学术健康系统内开展病例交叉研究,纳入2011年1月至2021年12月使用羟氯喹且至少一次因活动性系统性红斑狼疮住院的患者。较低体重剂量(≤5 vs >5 mg/kg/天)和非体重剂量(<400 vs 400 mg/天)均与活动性系统性红斑狼疮住院风险增加相关,调整后OR分别为4.20(95%CI 1.45-12.19)和3.39(95%CI 1.31-8.81)。
要点
- 较低体重剂量羟氯喹(≤5 vs >5 mg/kg/天)与活动性系统性红斑狼疮住院风险增加相关(调整OR 4.20)。
- 非体重剂量羟氯喹(<400 vs 400 mg/天)与活动性系统性红斑狼疮住院风险增加相关(调整OR 3.39)。
- 作者认为需在羟氯喹视网膜病变长期风险与系统性红斑狼疮活动短期及累积风险之间权衡。
核心结论
- 使用较低剂量羟氯喹与活动性系统性红斑狼疮住院风险增加相关。
- 作者认为,尽管必须承认羟氯喹视网膜病变的长期风险,但需将其与系统性红斑狼疮活动增加短期及累积风险相权衡。
研究设计与样本
- 在学术健康系统内开展病例交叉研究。
- 纳入使用羟氯喹且2011年1月至2021年12月期间至少一次因活动性系统性红斑狼疮住院的患者。
- 病例期为以系统性红斑狼疮住院结束的时期,对照期则否。
- 暴露为每个6个月病例期或对照期评估的平均体重剂量羟氯喹(≤5或>5 mg/kg/天)和非体重剂量羟氯喹(<400或400 mg/天)。
- 采用条件logistic回归计算比值比(OR),并调整既往疾病活动度、肾功能、糖皮质激素使用和其他免疫抑制剂使用。
主要发现
- 2,974例使用羟氯喹的系统性红斑狼疮患者(平均年龄36.5岁;92%女性)中,584例至少一次住院主要出院诊断为系统性红斑狼疮。
- 其中122例在使用羟氯喹期间至少一次因活动性系统性红斑狼疮住院,且研究期间至少一个使用羟氯喹的对照期。
- 较低体重剂量羟氯喹(≤5 vs >5 mg/kg/天)与活动性系统性红斑狼疮住院增加相关(调整OR 4.20,95%CI 1.45-12.19)。
- 非体重剂量羟氯喹(<400 vs 400 mg/天)与活动性系统性红斑狼疮住院增加相关(调整OR 3.39,95%CI 1.31-8.81)。
临床怎么用
- 作者认为,尽管必须承认羟氯喹视网膜病变的长期风险,但需将其与系统性红斑狼疮活动增加短期及累积风险相权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine the impact of hydroxychloroquine (HCQ) dose on the risk of hospitalizations for systemic lupus erythematosus (SLE). METHODS: We conducted a case-crossover study within an academic health system, including patients with SLE who used HCQ and had ≥1 hospitalization for active SLE between January 2011 and December 2021. Case periods ended in hospitalization for SLE, whereas control periods did not. The exposures were the average weight-based HCQ dose, categorized as ≤5 or >5 mg/kg/day, and non-weight-based HCQ dose, categorized as <400 or 400 mg/day, assessed during each six-month case or control period. Odds ratios (ORs) were calculated using conditional logistic regression and adjusted for prior disease activity, kidney function, glucocorticoid use, and other immunosuppressant use. RESULTS: Of 2,974 patients with SLE who used HCQ (mean age 36.5 years; 92% female), 584 had ≥1 hospitalization with primary discharge diagnosis of SLE. Of these, 122 had ≥1 hospitalization for active SLE while using HCQ and had ≥1 control period with HCQ use during the study period. Lower HCQ weight-based dose (≤5 vs >5 mg/kg/day) and non-weight-based dose (<400 vs 400 mg/day) were each associated with increased hospitalizations for active SLE (adjusted OR 4.20, 95% confidence interval [CI] 1.45-12.19, and adjusted OR 3.39, 95% CI 1.31-8.81). CONCLUSION: The use of lower doses of HCQ was associated with an increased risk of hospitalizations for active SLE. Although the long-term risk of HCQ retinopathy must be acknowledged, this must be balanced with the short-term and cumulative risks of increased SLE activity.
引用
- Nestor J, Choi H, Mancini C, et al. Hydroxychloroquine Dose and Hospitalizations for Active Lupus. Arthritis Rheumatol. 2024. PMID: 38831643. doi:10.1002/art.42924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。